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INTRODUCTION
S olid tumors do not progress without the oxygen influx and nutrient supply provided by tumor-associated microvascular networks (Folkman, 1971; Carmeliet, 2005; Naumov et al., 2006) . This fundamental observation led to the development of anti-angiogenic drugs, some of which have been approved for treatment of persons with cancer (e.g., Avastin, Genentech). An emerging concept is the potential use of anti-angiogenic strategies to block the progression of dormant lesions into progressive tumors as a means to convert cancer into a chronic manageable disease (Folkman and Kalluri, 2004) . This might be achievable through the control of the angiogenic switch, a process through which an avascular tumor begins to secrete angiogenic factors and becomes vascularized (Hanahan and Folkman, 1996) .
The mechanisms underlying the angiogenic switch are still not wellunderstood. However, enhanced expression of vascular endothelial growth factor (VEGF) appears to be associated with the process that "turns on" the angiogenic phenotype of tumor cells (Hanahan and Folkman, 1996; Bergers and Benjamin, 2003) . VEGF is the prototypic angiogenic factor with a well-established role in new vessel formation in both physiological and pathological conditions (Carmeliet, 2005; Ferrara, 2005) . VEGF also has a pro-endothelial cell survival function that is regulated by the activity of the anti-apoptotic Bcl-2 (Gerber et al., 1998; Nör et al., 1999) . The positive impact of Bcl-2 up-regulation in endothelial cells on the overall progression of tumors has been demonstrated in carcinoma and sarcoma tumor models (Nör et al., 2001a) . In contrast, inhibition of Bcl-2 expression in neovascular endothelial cells with RNA interference resulted in significant inhibition of tumor progression (Kaneko et al., 2007) .
Bcl-2's classic role is of an anti-apoptotic protein (Reed, 2006) . However, we have recently demonstrated that Bcl-2 also functions as a proangiogenic signaling molecule through signaling events involving NF-kB activation and up-regulation of expression of the pro-angiogenic CXCL1 (GRO-alpha) and CXCL8 (Interleukin-8) (Karl et al., 2005) . VEGF and CXCL8 were detected at higher concentrations in the serum of persons with head and neck cancer than in control individuals (Chen et al., 1999) . Notably, the expression of Bcl-2 in tumor-associated endothelial cells in persons with head and neck cancer is significantly higher than in endothelial cells of normal oral mucosa (Kaneko et al., 2007) . Taken together, these studies provide a conceptual framework for the inhibition of the VEGF-Bcl-2-CXCL8 signaling axis as a therapeutic strategy to prevent the angiogenic switch in head and neck tumors.
PTK/ZK (PTK787/ZK222584; Vatalanib; Novartis/Schering AG) is a small-molecule inhibitor of all known tyrosine kinase VEGF receptors (Drevs et al., 2000; Wood et al., 2000; Hess-Stumpp et al., 2005) . Its antiangiogenic and anti-tumor effects have been examined in pre-clinical studies, and in several clinical trials for cancers such as colorectal and thyroid cancer (Wood et al., 2000; Drevs et al., 2005; Yazici et al., 2005; Los et al., 2007; Steeghs et al., 2007) . PTK/ZK inhibited the phosphorylation of VEGFR2 ABSTRACT Transformation of small avascular masses of tumor cells into rapidly progressive cancers is triggered by the angiogenic switch, a process that involves vascular endothelial growth factor (VEGF) signaling. We have shown that VEGF enhances the survival and angiogenic potential of endothelial cells by activating the Bcl-2-CXCL8 signaling axis. The purpose of this study was to evaluate the effect of a small-molecule inhibitor of VEGF receptors (PTK/ZK) on the initial stages of head and neck tumor angiogenesis. In vitro, PTK/ ZK blocked head and neck tumor cell (OSCC3 or UM-SCC-17B)-induced Bcl-2 and CXCL8 expression in endothelial cells. Oral administration of PTK/ZK decreased xenograft head and neck tumor microvessel density, and inhibited Bcl-2 and CXCL8 expression in tumor-associated endothelial cells. Analysis of these data demonstrates that PTK/ZK blocks downstream targets of VEGF signaling in endothelial cells, and suggests that PTK/ZK may inhibit the angiogenic switch in head and neck tumors. Abbreviations: HDMEC, human dermal microvascular endothelial cells; VEGF, vascular endothelial growth factor; CXCL8, CXC ligand-8; PTK/ZK, PTK787/ZK222584. Key wORDS: Neovascularization, angiogenesis, developmental therapeutics, cancer.
in endothelial cells and decreased the microvessel density of xenografted head and neck carcinomas (Kim et al., 2006) . Here, we evaluated the effect of therapeutic inhibition of VEGF receptors with PTK/ZK on the early stages of head and neck tumor angiogenesis.
MATeRIALS & MeTHODS

Non-contact Co-culture in vitro Assays
Human Dermal Microvascular Endothelial Cells (HDMEC) (Cambrex, Walkersville, MD, USA) were cultured in endothelial cell growth medium (EGM2-MV, Cambrex). Human head and neck cancer cells (OSCC-3, gift from M. Lingen; and UM-SCC-17B, gift from T. Carey) were cultured in Dulbecco's modified Eagle's medium (DMEM; Gibco BRL, Grand Island, NY, USA) supplemented with 10% FBS, 1% L-glutamine, and penicillin and streptomycin. Non-contact co-culture in vitro assays were performed as previously described (Kaneko et al., 2007) . Cells were treated with 0-100 nM PTK/ZK (Novartis/Schering AG; Basel, Switzerland) or equivalent concentrations of vehicle (DMSO; Sigma, St. Louis, MO, USA). For details, see the APPENDIX.
western Blots
Whole-cell lysates were resolved by polyacrylamide gel electrophoresis, and membranes were probed overnight at 4°C with the following antibodies: polyclonal anti-human Bcl-2, 1:1000 dilution (51-1513 GR; BD Pharmingen, San Jose, CA, USA); polyclonal anti-human CXCL8, 1:2000 dilution (AF-208-NA; R&D Systems, Minneapolis, MN, USA); and monoclonal anti-human GAPDH, 1:100,000 dilution (MAB374; Chemicon International, Temecula, CA, USA). Proteins were visualized with the enhanced chemiluminescence detection kit (Supersignal West Pico; Pierce, Rockford, IL, USA).
SCID Mouse Model of Human Tumor Angiogenesis
Human xenograft tumors vascularized with human blood vessels were generated as described previously (Nör et al., 2001a,b) . For details, see the APPENDIX.
Laser Capture Microdissection
For Laser Capture Microdissection (LCM), tissue sections were incubated with 1:100 polyclonal anti-human Factor VIII antibody (Lab Vision, Fremont, CA, USA), followed by standard procedures for immunostaining. Approximately 2500 endothelial cells and 500,000 perivascular tumoral cells were microdissected per condition for each sample by means of a Leica AS LMD Laser Microdissection Microscope (LMD6000, Leica Microsystems Inc., Wetzlar, Germany), as previously described (Kaneko et al., 2007) .
RT-PCR and Real-time PCR Analyses
Bcl-2 and CXCL8 mRNA expression levels in endothelial or Densities of the bands for Bcl-2 and CXCL8 were measured with Image J software (NIH), normalized by the density of the respective GAPDH band, and represented numerically. The densities of the bands for vehicle-treated controls were set at "1" to facilitate interpretation of the data. (e,F) Real-time PCR used to quantify Bcl-2 (E) and CXCL8 (F) expression in endothelial cells (HDMEC) in co-cultures of UM-SCC-17B and HDMEC, or OSCC3 and HDMEC, and exposed to either PTK/ZK or vehicle control. These data represent the expression of Bcl-2 or CXCL8 normalized by the expression of the endogenous control 18S in each sample. The average normalized Bcl-2 or CXCL8 expression in the vehicle-treated group was set at "1". Statistical significance (asterisk) was determined at P ≤ 0.001, with respective vehicle-treated groups as controls.
tumor cells were evaluated by RT-PCR and by real-time PCR, as described (Kaneko et al., 2007) . For details, see the APPENDIX.
Data Analyses
T tests or one-way ANOVA were performed with SigmaStat 2.0 software (SPSS; Chicago, IL, USA) for analysis of data presented here. The significance level was set at p < 0.05.
ReSULTS
To understand the effect of the small-molecule inhibitor of VEGF receptor signaling PTK/ZK on Bcl-2 expression in primary human endothelial cells, we performed a dosedependency assay. Baseline Bcl-2 expression level in endothelial cells (HDMEC) is low. However, exposure to rhVEGF 165 induces Bcl-2 expression ( Fig. 1A) , as we have previously demonstrated (Nör et al., 1999) . Co-treatment of endothelial cells with VEGF and PTK/ZK resulted in a dosedependent decrease in Bcl-2 expression. Notably, 100 nM PTK/ZK brought Bcl-2 levels back to baseline, and 1000 nM essentially abrogated Bcl-2 expression in these cells. These data guided our choice for the use of 100 nM PTK/ZK for the remainder of the in vitro experiments performed here.
To simulate the in vivo conditions observed in the head and neck tumor microenvironment, we performed in vitro experiments using a non-contact co-culture method where endothelial cells were grown in the bottom chamber of 6-well plates, while the tumor cells were grown in the upper chamber (i.e., Transwell; Becton Dickinson, Franklin Lakes, NJ, USA). It is well-known that head and neck tumor cells express high levels of VEGF (Chen et al., 1999) . Therefore, in co-culture conditions, we observed that endothelial cell Bcl-2 expression in vehicle-treated controls (Fig. 1B) was consistently higher in single cultures of endothelial cells (Fig. 1A) . Notably, PTK/ZK treatment down-regulated Bcl-2 expression in the endothelial cells co-cultured with UM-SCC-17B (Fig. 1B) . In contrast, we did not observe a decrease in Bcl-2 protein expression in the UM-SCC-17B tumor cells in vitro (Fig.  1B) . To evaluate if PTK/ZK-mediated inhibition of Bcl-2 and CXCL8 expression was regulated at the transcriptional level, we repeated the same experimental design as above and performed RT-PCR from either the endothelial cells or the head and neck tumor cells. We observed that Bcl-2 and CXCL8 message in endothelial cells was down-regulated in PTK/ ZK-treated co-cultures, as compared with vehicle-treated (Figs. 1C, 1E,  1F ). We used a second squamous cell carcinoma cell line from the oral cavity (OSCC3) (Figs. 1D, 1E,  1F) , and observed that the effects of PTK/ZK were similar to those observed with UM-SCC-17B. These findings suggest that the effects of PTK/ZK reported here are not unique to one specific cell line.
To evaluate the effect of PTK/ ZK on tumor angiogenesis and tumor progression in vivo, we engineered human tumors vascularized with human blood vessels using the SCID Mouse Model of Human Angiogenesis (Nör et al., 2001a,b) . With this method, the HDMEC organize themselves into blood vessels that connect (anastomize) with the mouse vasculature and become functional (blood-carrying) vessels (Nör et al., 2001a) . At the end of the experimental period, macroscopic evaluation of the tumors revealed that PTK/ZK-treated tumors tended to be paler, as compared with vehicle-treated controls ( Fig. 2A) . Indeed, a decrease in microvessel density (p < 0.001) in PTK/ZK-treated animals was observed in both UM-SCC-17B and OSCC3 tumors, as compared with vehicletreated controls (Figs. 2B, 2C ). In addition, treatment of mice containing HDMEC-only scaffolds with PTK/ZK also resulted in a significant reduction in microvessel density as compared with controls (Figs. 2B, 2C) . We evaluated tumor progression over time to examine the anti-tumor effect of PTK/ZK administered as a single treatment. We observed that daily administration of single-agent PTK/ ZK resulted in a trend toward slower tumor progression (Fig. 3A) ; however, the differences between treated and untreated tumors were not statistically significant (P > 0.05). Notably, mice did not show significant signs of toxicity with the daily administration of 50 mg/kg PTK/ZK, as demonstrated by the absence of weight loss during the experimental period of 21 days (Fig.  3B) .
To quantify the effect of PTK/ ZK treatment on Bcl-2 expression in tumor-associated endothelial cells in vivo, we retrieved endothelial cells by LCM. Factor VIII immunostaining was used to identify tumor-associated endothelial cells (Fig. 4A ), blood cells were eliminated from the lumen of the vessels (Fig. 4B) , and endothelial cells were retrieved by LCM (Fig. 4C) . Finally, tumor cells were retrieved by standard LCM procedures. We observed that PTK/ZK down-regulated Bcl-2 expression in tumor-associated endothelial cells in vivo in both UM-SCC-17B ( Fig. 4D) and OSCC3 (Fig. 4E) xenograft tumors. Quantification of Bcl-2 expression levels in endothelial cells of UM-SCC-17B xenografts with real-time PCR revealed a significant down-regulation of Bcl-2 (approximately five-fold) in PTK/ZK-treated animals, as compared with vehicle-treated controls (Fig. 4G ). We observed that CXCL8 was downregulated in the endothelial cells of OSCC3 xenografts treated with PTK/ZK, as compared with vehicle-treated controls (Fig.  4E ). CXCL8 was also down-regulated in the tumor cells of The expression of CXCL8 in the endothelial cells from tumors generated by co-implantation of HDMEC and UM-SCC-17B (D) was found to be below detectable levels, as measured by RT-PCR. (F) RT-PCR analysis of the effect of PTK/ZK on Bcl-2 and CXCL8 expression in endothelial cells in scaffolds seeded only with HDMEC and implanted in SCID mice. (D-F) Densities of the bands for Bcl-2 and CXCL8 were measured with Image J software (NIH), normalized by the density of the respective GAPDH band, and represented numerically. The densities of the bands for vehicle-treated controls were set at "1" to facilitate interpretation of the data. (G) Real-time PCR used to quantify Bcl-2 expression in endothelial cells retrieved from tumors generated by the co-implantation of UM-SCC-17B and HDMEC in SCID mice that were treated with either PTK/ZK or vehicle control. These data represent the expression of Bcl-2 normalized by the expression of the endogenous control 18S in each sample. The average normalized Bcl-2 expression in the vehicle-treated group was set at "1". Statistical significance (asterisk) was determined at P < 0.001, with the vehicletreated group as control.
xenografts treated with PTK/ZK, but could not be detected in the endothelial cells of the UM-SCC-17B xenografts (Figs. 4D, 4E) . As an additional control, we implanted scaffolds that were seeded only with HDMEC ( Fig. 4F ). Endothelial cells collected from these scaffolds showed very low levels of Bcl-2 expression ( Fig. 4F) , presumably due to the absence of tumor cells as a source of VEGF. Notably, PTK/ZK was able to downregulate CXCL8 in the scaffolds seeded only with endothelial cells, as compared with vehicle-treated controls (Fig. 4F ).
DISCUSSION
Despite significant advances in the treatment and care of persons with cancer, the survival of persons with head and neck tumors has not improved significantly over the last 30 years. Local recurrence, second primary tumors, and metastatic disease are the most common causes of treatment failure in these individuals (Genden et al., 2003) . Therefore, the identification of persons at higher risk for recurrent or metastatic disease and the establishment of a chemopreventive protocol could be particularly beneficial for persons with head and neck cancer. Anti-angiogenic drugs tend to have fewer adverse effects than conventional chemotherapeutic drugs, and have been considered in chemopreventive schemes for prostate and head and neck cancer (Lingen, 1999; Singh and Agarwal, 2006; Noonan et al., 2007) . To begin to explore the potential of an inhibitor of VEGFR signaling as a chemopreventive strategy for head and neck cancer, we evaluated here the effects of PTK/ ZK in early stages of tumor angiogenesis.
PTK/ZK was selected for this study for several reasons: (A) It can be given orally, which could be beneficial for chemopreventive regimens. (B) PTK/ZK has been used extensively in pre-clinical studies and has reached Phase III clinical trials for the treatment of cancer (Wood et al., 2000; Solorzano et al., 2001; Los et al., 2007) . (C) PTK/ZK appears to have selectivity for the VEGF tyrosine kinase receptors (Hess-Stumpp et al., 2005) , which may explain the relatively mild nature of adverse effects observed with this drug. (D) The molecular targets of PTK/ZK, i.e., VEGF receptors, appear to be suitable candidates for chemopreventive schemes. For example, therapeutic inhibition of the VEGF/VEGFR2 signaling axis has been shown to be associated with the antitumor and anti-angiogenic effect of the vitamin A analogue fenretinide (4HPR) in highly vascularized Kaposi's sarcomas (Ferrari et al., 2003) . Taken together, these features make an inhibitor of VEGF receptors such as PTK/ZK an exciting candidate drug for preventive inhibition of the angiogenic switch in persons with head and neck cancer.
We have previously demonstrated that VEGF enhances the survival and angiogenic potential of endothelial cells by inducing Bcl-2 and CXCL8 expression (Nör et al., 1999; Karl et al., 2005) . We have also used a mathematical modeling approach and demonstrated that curtailing the synthesis of CXCL8 in early tumorigenesis significantly delays tumor progression and angiogenesis (Jain et al., 2008) . Furthermore, modeling showed that blocking Bcl-2 up-regulation in endothelial cells at early stages of tumor development ensures that both microvascular and tumor cell densities stabilize at low values, which can be translated as tumor growth control (Jain et al., 2008) . Here, we demonstrated that the PTK/ZK-mediated anti-angiogenic effect is associated with the inhibition of Bcl-2 and CXCL8 expression in the tumor-associated endothelial cells in two distinct xenograft head and neck tumor models. These results validated the putative downstream molecular targets of PTK/ZK in vivo. Our ability to quantify gene expression in the endothelial cells of tumors by laser-capture microdissection and quantitative RT-PCR allowed for an accurate analysis of the effectiveness of this anti-angiogenic drug in inhibiting its molecular targets. We believe that such an experimental approach is ideally suited for the validation of the effects of anti-tumor drugs on angiogenic signaling pathways in vivo.
In conclusion, this study demonstrates that oral administration of PTK/ZK has anti-angiogenic effects in early-stage head and neck tumors, which are accompanied by quantifiable inhibition of the VEGF-Bcl-2-CXCL8 signaling axis. Notably, effective blockade of the angiogenic switch with a chemopreventive strategy could potentially bring significant benefit to persons with head and neck cancer after management of the primary tumor, since recurrent or metastatic disease is frequent and has a major impact on the clinical outcome of these individuals.
